Oncology and Carcinogenesis articles for Canada

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 297

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
2 1.09
Enhanced Immunotherapy Efficacy through Molecularly Imprinted Nanoparticles Co-Targeting Cluster of Differentiation-73 and Programmed Death-Ligand 1 0.13
Invasive phenotypes of triple-negative breast cancer-associated fibroblasts are mechanosensitive, AhR-dependent and correlate with disease state 0.97
2 1.17
Engineering a Sonotherapeutic RBC Membrane‐Derived Nanoparticle Platform for the Treatment of Liver Cancer 0.95
A Single-Metal-Doped Nanoplatform for Ferroptosis-Driven cGAS-STING Pathway Activation in Hepatocellular Carcinoma Immunotherapy 0.21
1 1.00
Cold Atmospheric Plasma-Activated Decellularized Extracellular Matrix Gel as a Tumor-Infiltrating Immunoactivation Platform for Post-Surgical Cancer Immunotherapy 1.00
1 0.08
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention 0.08
2 0.81
Spatially Resolved Obesity-Driven Molecular Changes in Early Breast Cancer 0.08
YAP AND TEAD ARE TRANSCRIPTIONAL REGULATORS OF NEUROENDOCRINE DIFFERENTIATION AND GROWTH IN CARCINOID CELLS 0.73
1 0.05
A trans-omics gene-smoking interaction study of lung cancer based on consortium data 0.05
1 0.10
A Cell‐Resolved Ultrastable Biosensor Enables One‐Step Detection of Gene‐Fusion Transcripts in Unprocessed Whole Blood 0.10
1 0.11
Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups. 0.11
3 1.19
Plasma Cell-free DNA Methylomes for Hepatocellular Carcinoma Detection and Monitoring After Liver Resection or Transplantation. 1.00
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.10
Clinical and Pathologic features of 535 Patients with Congenital Mesoblastic Nephroma: A Report from the Children's Oncology Group. 0.09
5 0.32
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma 0.08
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma 0.04
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.03
Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma 0.03
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. 0.14
1 0.16
Deep learning analyses of splicing variants identify the link of PCP4 with amyotrophic lateral sclerosis 0.16
2 0.05
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.02
Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort study 0.03
2 0.03
A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies 0.01
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition 0.02
8 3.47
Enozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations. 0.03
Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. 0.06
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy 0.57
Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy 0.99
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type 0.08
Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation 0.71
Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR T Cells against Hematologic Malignancies 0.04
An Anti-EGFR Antibody–Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer 1.00
2 1.15
Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells 0.98
TET2-mutant myeloid cells mitigate Alzheimer’s disease progression via CNS infiltration and enhanced phagocytosis in mice 0.17
2 0.85
Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. 0.22
Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension 0.63
1 0.92
Occupational exposure to endocrine-disrupting chemicals and colorectal cancer risk - An analysis of four participating cohorts of the Canadian Partnership for Tomorrow’s Health study 0.92
1 1.00
Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers 1.00
5 0.32
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer 0.03
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study 0.10
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder 0.05
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial 0.05
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial 0.10
4 0.77
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial 0.57
Depletion of Fibrinogen Suppresses Growth of Primary Tumors and Metastasis of Pancreatic Ductal Adenocarcinoma 0.13
Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma 0.05
Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation 0.03
3 0.83
Multiomic analysis of clonal development reveals new regulators of leukemic cell growth 0.06
Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer 0.07
ERRγ impedes neuroendocrine prostate cancer development 0.70
2 0.50
Alternative splicing generates HER2 isoform diversity underlying antibody–drug conjugate resistance in breast cancer 0.13
Comprehensive functional annotation of ESR1-driven enhancers in breast cancer reveals hierarchical activity independent of genomic and epigenomic contexts 0.37
1 0.04
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.04
2 0.09
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.04
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.05
1 0.70
A fungal-derived adjuvant amplifies the antitumoral potency of Bacillus Calmette-Guérin via reprogramming granulopoiesis 0.70
2 0.13
Macropa Scaffold Expansion for Actinium-225 Chelation: A Synthetic Strategy, Labeling Kinetics, and Theoretical Calculations 0.09
Heavy Alkaline Earth Radiometals for Cancer Theranostics: Coordination and Radiochemistry of Radium-223 and Barium-131 with Kryptofix 22-Based Chelators 0.04
1 0.03
Maternal prenatal infection and childhood leukaemia: a Childhood Cancer and Leukemia International Consortium (CLIC) meta-analysis 0.03
4 1.86
AI–Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma 0.05
Esophagectomy vs Active Surveillance in Clinical Complete Responders After Neoadjuvant Chemoradiation 0.81
Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer 0.93
Long-Term Locoregional Outcomes in a Contemporary Cohort of Young Women With Breast Cancer 0.07
2 0.13
Biomarker-Based Eligibility for Lung Cancer Screening: Validation of the Protein-Based INTEGRAL-Risk Model. 0.06
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis 0.08
9 7.61
microRNAs bidirectionally regulate FUT1 to modulate α-1,2-fucosylation and cancer-associated biology 1.00
Platelet CLEC-2 activation leads to GPIb⍺ shedding: implications for doxorubicin chemotherapy and thrombosis 1.00
Crystal structure of RohS, a heme-oxygenase-like N-oxygenase from azomycin biosynthesis 0.88
RNA-Binding Proteins TDP-43 and FUS Promote R-Loop Resolution and Regulate Transcription Termination 1.00
Creatine kinase B promotes non–small cell lung cancer survival and metastasis 1.00
Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism 0.07
CLIC5A binds to and stabilizes the open and active conformation of ezrin 1.00
Metabolomics analysis of SNAT2-deficient cells: Implications for the discovery of selective small-molecule inhibitors of an amino acid transporter 0.67
Symmetric stimulation of Hsp90 catalyzed ATP hydrolysis through enhanced active site gate dynamics 1.00
1 0.79
Trends and Impact of Pharmacological VTE Prophylaxis Timing for Traumatic Cervical Spinal Cord Injury Across North American Trauma Centers 0.79
2 0.20
Moesin controls cell–cell fusion and osteoclast function 0.04
Telomeric SUMO level influences the choices of APB formation pathways and ALT efficiency 0.17
10 2.24
Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity 0.06
SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis 0.09
CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer 0.03
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression 0.64
Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1 1.00
USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer 0.05
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia 0.08
BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature-positive castration-resistant prostate cancer 0.10
TNF-α impairs platelet function by inhibiting autophagy and disrupting metabolism via syntaxin 17 downregulation 0.04
PROX1 is an early driver of lineage plasticity in prostate cancer 0.15
23 5.25
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.11
Concurrent versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of “High Risk” Early Breast Cancer: NRG/RTOG 1005 Phase III Trial 0.12
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. 0.07
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.02
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. 0.03
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. 0.09
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2. 0.40
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer. 0.12
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.21
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma. 0.05
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.09
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.04
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. 0.07
Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533. 0.11
Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. 0.97
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report. 0.14
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.03
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. 0.58
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.02
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. 0.13
Mindfulness and Tai Chi for Cancer Health (MATCH) Study: Primary Outcomes of a Preference-Based Multisite Randomized Comparative Effectiveness Trial. 0.88
Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer. 0.94
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.03
2 1.06
Tauroursodeoxycholic acid (TUDCA) ameliorates age‐related skeletal muscle loss 0.06
The mitochondrial‐targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial‐apoptotic but not necroptotic signalling during ovarian cancer 1.00
2 0.54
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer 0.14
The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: results from CALGB 140503 (Alliance) 0.40
1 0.17
Translating a miRNA Signal into Physical Immunomodulation via Programmed DNA Network Assembly on Mitochondria 0.17
1 0.91
Association of Palliative Care Initiation With Acute Healthcare Utilization Among Community‐Dwelling Adults Living With Dementia 0.91
13 2.64
Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study 0.07
Postpartum breast cancer: evidence for a distinct phenotype 0.04
Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment 0.92
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials 0.14
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.03
Personalizing lung cancer screening recommendations for heterogenous populations: a microsimulation study 0.14
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.02
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance) 0.06
Mortality after colorectal cancer among survivors of childhood cancer 0.13
Breastfeeding after breast cancer in young iBRCA/i carriers 0.02
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.00
Cardiometabolic outcomes after bariatric surgery in adult survivors of childhood cancer: a St Jude Lifetime Cohort report 0.07
Sexual health outcomes after colorectal cancer diagnosis in females: a population-based cohort study 1.00
1 0.08
Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy 0.08
1 0.11
mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport 0.11
10 1.68
Evolutionary characterization of lung cancer metastasis 0.01
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma 0.42
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma 0.02
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.06
Somatic evolution following cancer treatment in normal tissue 0.01
Anti-progestin therapy targets hallmarks of breast cancer risk 0.06
Molecular subtypes of human skeletal muscle in cancer cachexia 0.86
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy 0.10
A missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia 0.08
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.06
1 0.75
Epigenetic alterations facilitate transcriptional and translational programs in hypoxia 0.75
1 0.15
ELOVL6 activity attenuation induces mutant KRAS degradation 0.15
54 16.19
Potential for risk reduction of chronic health conditions through lifestyle in childhood cancer survivors 0.13
Allosteric network of dynamic coupling within BAP1-UCH revealed by methyl NMR 0.03
ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer 0.11
Tumor sialylation regulates G-CSF stability and promotes neutrophil-mediated immunosuppression in breast cancer 0.05
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial 0.83
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial 0.03
Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22 0.06
SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity 0.05
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response 0.05
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial 0.02
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.09
HR3/RORα-mediated cholesterol sensing regulates TOR signaling 0.44
Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcoma 0.86
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study 0.06
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study 0.04
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma 0.92
USP7 deubiquitinase stabilizes FAN1 to support DNA crosslink repair and suppress CAG repeat expansion 0.12
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer 0.97
The N-Myc MB0-MBI region interacts specifically and dynamically with the N-lobe of Aurora kinase A 0.27
Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy 0.11
Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4 0.17
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma 0.02
Splice isoform-perturbation coupled to single cell transcriptome profiling reveals functions of microexons in neurogenesis and autism-linked pathways 0.81
De novo variants in the splicing factor gene are associated with neurodevelopmental disorders 0.12
RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance 0.05
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial 1.00
Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer 0.13
Synovial sarcoma reprograms transcription by GBAF activation of polycomb targets and loss of CBAF enhancers 0.29
The molecular cartography of malignant and benign sebaceous tumours 0.04
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer 0.22
LncRNA regulates cell size in human and mouse by guiding FOSL2 0.94
Early genetic evolution of driver mutations in uveal melanoma 0.03
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction 0.15
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations 0.05
The fibroblast epigenome underlies SS18::SSX-mediated transformation in synovial sarcoma 0.77
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination 0.05
N-terminal α-amino SUMOylation promotes phosphorylation-independent cofilin-1 translocation to the mitochondrial matrix and induces apoptosis 0.10
WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response 0.39
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer 0.04
Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia 0.05
CryoEM and computational modeling structural insights into the pH regulator NBCn1 0.31
Pathogenic variants in cause an X-linked neurodevelopmental disorder modulated by NURF complex composition 0.12
Single rate-limiting event of carcinogenesis 0.75
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer 0.03
The Hippo terminal effector YAP boosts enterovirus replication in type 1 diabetes 0.04
Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry 0.04
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial 0.10
Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer 1.00
Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression 0.08
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas 0.10
Aberrant EZHIP expression drives tumorigenesis in osteosarcoma 1.00
Inferring chromosome segregation error stage and crossover in trisomic disorders with application to Down syndrome 0.05
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial 0.94
O-GlcNAcylation of FOXK1 co-opts BAP1 to orchestrate the E2F pathway and promotes oncogenesis 1.00
5 2.00
Transposable elements shape stemness in normal and leukemic hematopoiesis 0.89
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.08
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.02
Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma 0.80
Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas 0.21
1 0.35
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma 0.35
11 1.43
CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial 0.04
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial 0.04
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.12
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma 0.40
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial 0.06
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial 0.35
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study 0.08
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial 0.09
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses 0.03
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial 0.08
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial 0.14
2 1.03
Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy 0.03
A modular mRNA platform for programmable induction of tumour-specific immunogenic cell death 1.00
1 0.22
Vitamin B2 metabolism promotes FSP1 stability to prevent ferroptosis 0.22
1 0.89
Reactive oligodendrocytes promote glioblastoma progression through CCL5/CCR5-mediated glioma stem cell maintenance 0.89
1 1.00
Total Synthesis of Orbiculamide A 1.00
1 0.04
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma 0.04
1 0.08
Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and mendelian randomization analysis. 0.08
14 8.26
CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling 0.89
Unveiling the developmental and tumor-suppressive roles of the p53 variant p53psi 0.84
Ubiquitin-specific peptidase-19 links TDP-43 aggregation to ER stress 0.09
ARP2/3 complex mediates the neuropathology of PTEN-deficient human neural cells downstream of mTORC1 and mTORC2 hyperactivation 0.85
Bioresponsive immunomodulator nanocomplex for selective immunoengineering in metastatic lymph nodes 1.00
E2 variants for probing E3 ubiquitin ligase activities 0.20
Potentiation of ryanodine receptor–mediated calcium release by MAPK is responsible for epidermal transformation and carcinogenesis 0.45
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer 0.59
Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target 0.10
Intracellular pH regulates ubiquitin-mediated degradation of the MAP kinase ERK3 0.62
Kupffer cells are essential for platelet-mediated thrombopoietin generation in the liver 0.80
Yeast centrosomes act as organizing centers to promote Polo kinase–mediated adaptation to persistent DNA damage 1.00
Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer 0.79
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activity 0.04
2 0.59
Cryo–electron microscopy structure of the budding yeast telomerase holoenzyme 0.57
A non-enzymatic role of Nudix hydrolase 5 in repressing purine de novo synthesis 0.02
5 1.29
TP53-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition 1.00
PARP4 ADP-ribosylates PIDD1 to complete a phospho/SUMO/PAR-ylation cascade that orchestrates PIDDosome assembly 0.17
A synergistic interaction between PRMT5 and LSD1 inhibitors in AML 0.03
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup 0.03
Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTs 0.06
7 3.44
uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target 0.99
Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers 0.02
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses 0.01
CAR Treg cells mediate linked suppression and infectious tolerance in islet transplantation in mice 0.82
Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models 0.50
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis 0.77
Podocyte YAP and TAZ hyperactivation drives glomerular epithelial proliferative diseases in mice and humans 0.34
4 0.75
NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation 0.15
Molecular basis for the activation of Aurora A and Plk1 kinases during mitotic entry 0.20
The transaminase-ω-amidase pathway senses oxidative stress to control glutamine metabolism and α-ketoglutarate levels in endothelial cells 0.05
Concurrence of mutations modulates oncogenesis in glioneuronal tumors 0.35
6 0.38
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial 0.08
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.03
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials 0.13
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.05
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.04
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
18 1.70
Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study 0.17
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial 0.08
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration 0.11
Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study 0.04
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.01
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.02
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.04
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.02
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.06
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 0.10
Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study 0.56
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis 0.09
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.05
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis 0.13
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group 0.03
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 0.09
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial 0.03
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study 0.06
19 2.49
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer 0.05
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations 0.03
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.02
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.03
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.04
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.05
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.05
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.06
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 0.10
Nivolumab for Resected Stage III or IV Melanoma at 9 Years 0.03
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.05
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.02
Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis 0.96
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 0.04
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.07
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.04
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.04
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer 0.74
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 0.07
1 0.03
Upstaging of screen-detected lung cancers during diagnostic assessment 0.03

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.